Posted by Michael Wonder on 10 May 2025
MeiraGTx granted FDA regenerative medicine advanced therapy designation for AAV-GAD for the treatment of Parkinson’s disease
9 May 2025 - This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson’s disease.
MeiraGTx today announced that the US FDA has granted regenerative medicine advanced therapy designation to AAV-GAD for the treatment of Parkinson’s disease not adequately controlled with anti-Parkinsonian medications.
